Your browser doesn't support javascript.
loading
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Danne, Thomas; Edelman, Steven; Frias, Juan Pablo; Ampudia-Blasco, Francisco Javier; Banks, Philip; Jiang, Wenjun; Davies, Michael J; Sawhney, Sangeeta.
Afiliação
  • Danne T; Diabetes-Zentrum für Kinder und Judendliche, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany.
  • Edelman S; Department of Medicine, University of California San Diego, Veterans Affairs Medical Center, San Diego, California.
  • Frias JP; Taking Control of Your Diabetes, Solana Beach, California.
  • Ampudia-Blasco FJ; National Research Institute, Los Angeles, California.
  • Banks P; Diabetes Reference Unit, Endocrinology and Nutrition Department, Clinic University Hospital and INCLIVA Biomedical Research Institute, Valencia, Spain.
  • Jiang W; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas.
  • Davies MJ; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas.
  • Sawhney S; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas.
Diabetes Obes Metab ; 23(3): 854-860, 2021 03.
Article em En | MEDLINE | ID: mdl-33289297
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Inibidores do Transportador 2 de Sódio-Glicose Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Inibidores do Transportador 2 de Sódio-Glicose Idioma: En Ano de publicação: 2021 Tipo de documento: Article